A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.

Trial Profile

A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Cardiovascular disorders; Thrombosis
  • Focus Therapeutic Use
  • Acronyms LIPT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2016 Results assessing effect of liraglutide on ectopic fat distribution and sex hormones in patients with polycystic ovary syndrome (n=67) presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 03 Mar 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top